• This study assessed the effects of haloperidol for prevention and treatment of delirium in adult patients.
Introduction
Delirium is a neuropsychiatric disorder characterized by an acute onset of confusion and alterations of consciousness [1, 2] , resulting in increased complications, prolonged hospitalization, and worse outcomes [3] [4] [5] . The incidence of delirium ranges from 29 to 64% in medical in-patients [3, 4] and even higher in intensive and palliative care settings [5] . The risk factors include elderly patients, cognitive impairment, prior delirium, abnormal sodium, potassium or glucose, preoperative narcotics, tobacco or psychotropic drug use, apolipoprotein E4 carrier status, and postoperative hypotension [6] [7] [8] [9] [10] [11] .
Haloperidol, a typical antipsychotic, is still used widely to treat delirium. However, the results from previous studies are inconsistent. Several studies reported that the use of haloperidol was associated with a decrease in delirium incidence [12] [13] [14] [15] , while others did not report a beneficial effect of haloperidol [16] [17] [18] [19] . It was also reported that prophylactic low-dose haloperidol did not reduce the incidence of delirium [20, 21] .
Recently, 2 reviews showed promising results on haloperidol for delirium management, but they failed to summarize the evidence by means of a quantitative metaanalysis [22, 23] . Hence, a systematic review and metaanalysis were designed to assess the effects of haloperidol for the prevention and treatment of delirium in adult patients.
Materials and Methods

Literature Search
Two researchers (Y.S. and K.P.) independently performed a comprehensive literature search to identify trials that compared the effects of haloperidol with placebo or antipsychotics on the outcomes of delirium in adult patients. PubMed, Embase, the Cochrane Library, Elsevier, Wiley, and Ovid were searched until May 1, 2017. A basic search was performed using medical subject headings and free text words: "haloperidol," "antipsychotics," and "delirium." No language or publication date restriction was applied. In addition, references and previous reviews were manually checked for other potentially eligible trials. Any disagreement at any stage of this study was resolved by group discussion and consensus.
The inclusion criteria were adult patients, haloperidol prophylaxis or treatment, comparisons of haloperidol with placebo or second-generation antipsychotics, delirium-related outcomes, randomized controlled trials (RCTs), and prospective interventional cohort trials. The search flow diagram is shown in Figure 1 . A total of 272 articles relevant to the search terms were identified, and 10 studies were finally included in this study.
Data Extraction and Quality Assessment
The following data were independently extracted by 2 reviewers (Y.S. and K.P.): first author, year of publication, study design, inclusion and exclusion criteria, interventions, number of patients, and outcomes. The primary end point was the incidence and severity of delirium. Secondary end points were the duration of delirium, mortality, length of intensive care unit (ICU) stay, length of hospital stay, and the incidence of corrected QT (QTc) interval prolongation and extrapyramidal symptoms. The severity of delirium was measured by revised Delirium Rating Scale (DRS-R98) scores, and Mini-Mental State Examination (MMSE) scores.
The methodological quality of each included study was evaluated using the Cochrane risk of bias assessment tool [24] . Disagreements on data abstraction and quality assessment were resolved by group discussion.
Statistical Analysis
All analyses were performed using Review Manager 5.3 (The Cochrane Collaboration, Copenhagen, Denmark). Dichotomous variables, including the incidence of delirium, mortality, QTc interval prolongation, and extrapyramidal symptoms, were reported as the risk ratio (RR) with 95% confidence interval (CI), while mean difference (MD) with 95% CI was used for the continuous variables, including the duration of delirium, ICU stay, hospital stay, DRS-R98 scores, and MMSE scores. The results of risperidone and olanzapine groups were combined using the calculator in Revman [25] . A p value < 0.05 was considered statistically significant.
The heterogeneity among studies was assessed using the I 2 test. If the I 2 index was ≤50%, the fixed-effect model was selected to calculate the pooled effects; otherwise, a random-effect model was used [24, 26] . The following sensitivity analyses were performed to test the robustness of the results: (a) whether the quality of publication (RCT or non-RCT) could influence the results, and (b) subgroup analyses according to the data of surgical versus ICU settings and high doses (≥5 mg) versus low doses (< 5 mg) of haloperidol.
Results
Study Selection and Characteristics
The study characteristics are described in Table 1 . The patient populations ranged from 63 to 457. Seven studies were RCTs, 2 were randomized, open-label prospective trials, and 1 was a prospective interventional cohort study [12-19, 25, 27] . A risk assessment of the included studies is presented in Table 2 .
Haloperidol versus Placebo for Delirium Prophylaxis
Eight studies [12] [13] [14] [15] [16] [17] [18] [19] compared haloperidol with placebo for preventing delirium in surgical and ICU patients. Overall, haloperidol prophylaxis did not decrease the incidence of delirium compared with placebo (RR 0.84, 95% CI 0.62, 1.13, p = 0.24, I 2 = 55%; Fig. 2 ) [12] [13] [14] [15] [16] [17] [18] . Subgroup analysis based on surgical versus ICU patients did not detected any significance with I 2 = 58.6% (Fig. 2a) . Subgroup analysis based on haloperidol doses showed that the use of a high dose of haloperidol (≥5 mg/day) may reduce the incidence of delirium (RR 0.50, 95% CI 0.32, 0.79, p = 0.003, I 2 = 0%; Fig. 2b ). Of the 8 studies, 5 [12, [16] [17] [18] [19] showed that haloperidol prophylaxis did not shorten the duration of delirium (MD -0.75 days, 95% CI -1.97, 0.46, p = 0.22, I 2 = 84%; Fig. 3a) .
In the sensitivity analyses, the I 2 index values in the outcome of delirium incidence remained above 30%. Substantial heterogeneity of I 2 = 57% was found when we included only RCTs. For the outcome of duration of delirium, substantial heterogeneity still existed (I 2 = 86%) when only RCTs were included.
Regarding the side effects associated with haloperidol, 3 studies [11, 15, 16] showed that there were no differences in QTc interval prolongation or the incidence of extrapyramidal symptoms (Fig. 3b, c) . In addition, there were no differences in ICU stay, hospital stay, or mortality between the haloperidol and placebo groups (Fig. 4) .
Haloperidol versus Second-Generation Antipsychotics for Delirium Treatment
For delirium treatment, no difference was found in DRS-R98 or MMSE scores at 0, 3, and 6 days between the haloperidol and second-generation antipsychotics treatment groups (Fig. 5, 6 ) [24, 26] .
Discussion
This systematic review and meta-analysis suggests that a high dose (≥5 mg/day) of haloperidol prophylaxis might help reduce delirium in surgical patients. However, use of haloperidol did not influence the duration of delirium, QTc interval prolongation, extrapyramidal symptoms, ICU stay, hospital stay, or mortality. For delirium treatment, haloperidol had similar therapeutic effects on MMSE and DRS-R98 scores as the second-generation antipsychotics. Subgroup analysis showed that a high dose of haloperidol (≥5 mg/day) reduced the incidence of delirium in surgical patients. However, more evidence is needed due to the limited number of studies included for this outcome. Kalisvaart et al. [12] used a small dose of haloperidol (1.5 mg/day) and found no difference in delirium outcomes between the groups. Wang et al. [15] also used a small dose (0.5 mg intravenous bolus injection followed by continuous infusion of 0.1 mg/h for 12 h) and reported a lower incidence of delirium in the haloperidol group, suggesting that continuous infusion may be a better choice. Besides, initiating the therapeutic intervention as early as possible by detecting the early signs of delirium is essential for preventing its aggravation. With regard to the early stage of postoperative delirium, a concept exists called "subsyndromal delirium" [28] [29] [30] [31] , which is a frequent and clinically important condition that falls on a continuum between no symptoms and full delirium. The importance of starting the prophylactic intervention during the subsyndromal stage has also been reported. Hakim et al. [32] showed that early treatment with risperidone during the subsyndromal phase had a preventative effect against postoperative delirium after on-pump cardiac surgery in the elderly.
A higher dose of haloperidol may cause a higher incidence of side effects. In the study by Page et al. [19] the incidences of QTc interval prolongation and extrapyramidal symptoms in the haloperidol group were 9.86 and 2.82%, respectively, compared to 1.75 and 0% in the study by Wang et al. [15] with a low dose of 1.7 mg/day. Currently, a dose of 3-5 mg/day of haloperidol is suggested, but the therapy for delirium still needs be tailored to the characteristics of each individual [33] [34] [35] .
The limitations of this study include the fact that a small number of studies met the inclusion criteria, hence the sample size was relatively small. Further limitations were the heterogeneity of the included studies, the fact that other medications such as dexmedetomidine were reported to have aided in the reduction of postoperative delirium, and the lack of a placebo group for the comparison of haloperidol with second-generation antipsychotics for delirium treatment.
Conclusion
In this systematic review and meta-analysis, haloperidol prophylaxis with a dose of ≥5 mg/day might help reduce the incidence of delirium in surgical patients. For the treatment of delirium, haloperidol exhibited similar effects as the second-generation antipsychotics. However, more studies are required to investigate the optimal regimen for the prophylaxis and treatment of delirium in high-risk patients. 
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